Mr. Rif kin asked to put aside definitions and to look at 
principle. He once again cited the Wistar experiment and asked 
Dr. Gottesman if she felt the research in Argentina was a 
"direct extension." 
Dr. Gottesman replied she was on the working group and that the 
wording "direct extension" was put into the recommendation 
because it was the consensus of that group that the field trial 
was a direct extension, that it was clearly what had to be done 
next in development of the rabies vaccine. 
Mr. Rif kin said it was important to him to have the principle 
established rather than argue semantics so that in the future 
there would be no problem in interpreting the NIH Guidelines. 
After the luncheon recess, Dr. McGarrity called the committee to 
order and asked for pertinent discussion and comments with an aim 
toward a closure on the subject. 
Dr. Gottesman said since she was an ad hoc member of the RAC and 
had no voting privileges she would proffer some text for the 
group to work on. She proposed a revision of Section I-C of the 
NIH Guidelines to read as follows: 
"The NIH Guidelines are also applicable to recombinant 
DNA projects done abroad: (1) if they are supported by 
NIH funds or conducted at, or sponsored by, an 
institution that receives any support for recombinant 
DNA research from NIH; and (2) if it involves 
deliberate release into the environment or testing in 
humans of materials containing recombinant DNA 
developed with NIH funds and the research is a direct 
extension of an NIH-supported project. 
"If the host country, however, has established rules of 
conduct of recombinant DNA projects, then a written 
assurance of compliance with those rules may be 
submitted to NIH in lieu of compliance with the NIH 
Guidelines. Alternatively, if the host country does 
not have such rules, written acceptance of the proposed 
project by an appropriate Government office of the host 
country is necessary. The NIH reserves the right to 
withhold funding if the safety practices to be employed 
abroad are not reasonably consistent with the NIH 
Guidelines . " 
Dr. Gottesman said she knew of an alternatively worded proposal 
which was somewhat simpler and asked if, after having it read, a 
straw vote could be taken on which alternative to discuss 
further . 
[150] 
Recombinant DNA Research, Volume 13 
